

# SAFETY DATA SHEET



## Ezetimibe Formulation



Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

### SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ezetimibe Formulation

#### Manufacturer or supplier's details

Company name of supplier : Organon & Co.  
Address : Avenida 16 de Septiembre No. 301  
Xaltocan - Xochimilco Mexico 16090  
Telephone : 52 55 57284444  
Emergency telephone : 215-631-6999  
E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification

Skin irritation : Category 3

#### GHS label elements

Signal Word : Warning

Hazard Statements : H316 Causes mild skin irritation.

Precautionary Statements : **Response:**  
P332 + P313 If skin irritation occurs: Get medical advice/ attention.

#### Other hazards

Dust contact with the eyes can lead to mechanical irritation.  
May form explosive dust-air mixture during processing, handling or other means.

---

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 20 -< 30
Ezetimibe	163222-33-1	>= 10 -< 20
Sodium n-dodecyl sulfate	151-21-3	>= 1 -< 3
Magnesium stearate	557-04-0	>= 1 -< 5
2-Pyrrolidone	616-45-5	>= 0.1 -< 1

---

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

---

# SAFETY DATA SHEET



## Ezetimibe Formulation



Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes mild skin irritation.  
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.
- 

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Fluorine compounds  
Sulfur oxides  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- 

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

# SAFETY DATA SHEET



## Ezetimibe Formulation



Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## Ezetimibe Formulation

Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
 Date of first issue: 21.10.2014

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	VLE-PPT	10 mg/m <sup>3</sup>	NOM-010-STPS-2014
		TWA	10 mg/m <sup>3</sup>	ACGIH
Ezetimibe	163222-33-1	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	VLE-PPT	10 mg/m <sup>3</sup>	NOM-010-STPS-2014
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapor type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially

# SAFETY DATA SHEET



## Ezetimibe Formulation



Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

contaminated clothing.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	off-white
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

# SAFETY DATA SHEET



## Ezetimibe Formulation



Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

Oxidizing properties : The substance or mixture is not classified as oxidizing.  
Molecular weight : No data available  
Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.  
Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

#### Components:

##### Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

##### Ezetimibe:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 5,000 mg/kg

# SAFETY DATA SHEET



## Ezetimibe Formulation



Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

LD50 (Dog): > 3,000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 2,000 mg/kg  
Application Route: Intraperitoneal

LD50 (Mouse): > 1,000 - < 2,000 mg/kg  
Application Route: Intraperitoneal

### **Sodium n-dodecyl sulfate:**

Acute oral toxicity : LD50 (Rat): 1,200 mg/kg  
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Remarks: Based on data from similar materials

### **Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

### **2-Pyrrolidone:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 401  
Assessment: The substance or mixture has no acute oral toxicity

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

### **Skin corrosion/irritation**

Causes mild skin irritation.

### **Components:**

#### **Ezetimibe:**

Species : Rabbit  
Result : No skin irritation

#### **Sodium n-dodecyl sulfate:**

Species : Rabbit

# SAFETY DATA SHEET



## Ezetimibe Formulation



Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

Result : Skin irritation

### **Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

### **2-Pyrrolidone:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

### **Serious eye damage/eye irritation**

Not classified based on available information.

### **Components:**

#### **Ezetimibe:**

Species : Rabbit  
Result : No eye irritation

#### **Sodium n-dodecyl sulfate:**

Species : Rabbit  
Result : Irreversible effects on the eye  
Method : OECD Test Guideline 405

#### **Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

#### **2-Pyrrolidone:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 7 days

### **Respiratory or skin sensitization**

#### **Skin sensitization**

Not classified based on available information.

#### **Respiratory sensitization**

Not classified based on available information.

### **Components:**

#### **Ezetimibe:**

Test Type : Maximization Test  
Species : Guinea pig  
Result : negative



## Ezetimibe Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.2	16.10.2020	23839-00016	Date of first issue: 21.10.2014

---

**Sodium n-dodecyl sulfate:**

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Result	:	negative
Remarks	:	Based on data from similar materials

**Magnesium stearate:**

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

**2-Pyrrolidone:**

Test Type	:	Local lymph node assay (LLNA)
Routes of exposure	:	Skin contact
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative
Remarks	:	Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

**Ezetimibe:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Metabolic activation: with and without metabolic activation Result: negative
		Test Type: Chromosomal aberration Test system: Human lymphocytes Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse

## Ezetimibe Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.2	16.10.2020	23839-00016	Date of first issue: 21.10.2014

---

Cell type: Bone marrow  
Application Route: Oral  
Result: negative

**Sodium n-dodecyl sulfate:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**2-Pyrrolidone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Method: OECD Test Guideline 474  
Result: negative



## Ezetimibe Formulation

Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Ezetimibe:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Fertility: NOAEL: > 1,000 mg/kg body weight  
Result: No effects on fertility., No fetotoxicity.

Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
Result: No adverse effects.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
Result: No adverse effects.

**Sodium n-dodecyl sulfate:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 416  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

## Ezetimibe Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.2	16.10.2020	23839-00016	Date of first issue: 21.10.2014

---

**2-Pyrrolidone:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: positive  
 Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: positive

Reproductive toxicity - Assessment : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Cellulose:**

Species : Rat  
 NOAEL :  $\geq 9,000$  mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days

**Ezetimibe:**

Species : Dog  
 NOAEL : 1,000 mg/kg  
 Application Route : Oral  
 Exposure time : 90 d  
 Remarks : No significant adverse effects were reported

Species : Rat  
 NOAEL : 1,500 mg/kg  
 Application Route : Oral  
 Exposure time : 90 d  
 Remarks : No significant adverse effects were reported

Species : Mouse  
 NOAEL : 500 mg/kg  
 Application Route : Oral  
 Exposure time : 90 d  
 Remarks : No significant adverse effects were reported

Species : Dog  
 NOAEL : 300 mg/kg

# SAFETY DATA SHEET



## Ezetimibe Formulation



Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

Application Route : Oral  
Exposure time : 1 y  
Remarks : No significant adverse effects were reported

### **Sodium n-dodecyl sulfate:**

Species : Rat  
NOAEL : 488 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### **Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### **2-Pyrrolidone:**

Species : Rat  
NOAEL : 207 mg/kg  
Application Route : Ingestion  
Exposure time : 3 Months  
Method : OECD Test Guideline 408

### **Aspiration toxicity**

Not classified based on available information.

### **Components:**

#### **Ezetimibe:**

Not applicable

### **Experience with human exposure**

#### **Components:**

#### **Ezetimibe:**

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

---

## SECTION 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

#### **Components:**

#### **Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

---

## Ezetimibe Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.2	16.10.2020	23839-00016	Date of first issue: 21.10.2014

---

**Ezetimibe:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 203  
 Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 4 mg/l  
 Exposure time: 48 h  
 Method: OECD Test Guideline 202  
 Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 201  
 Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 201  
 Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l  
 Exposure time: 33 d  
 Method: OECD Test Guideline 210

NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l  
 Exposure time: 7 d  
 Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.282 mg/l  
 Exposure time: 21 d  
 Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 4.4 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209  
 Remarks: No toxicity at the limit of solubility.

NOEC: 4.4 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209  
 Remarks: No toxicity at the limit of solubility.

**Sodium n-dodecyl sulfate:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 29 mg/l  
 Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 5.55 mg/l  
 Exposure time: 48 h

## Ezetimibe Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.2	16.10.2020	23839-00016	Date of first issue: 21.10.2014

---

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l  
Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l  
Exposure time: 72 h

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): >= 1.357 mg/l  
Exposure time: 42 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Ceriodaphnia dubia (water flea)): 0.88 mg/l  
Exposure time: 7 d

Toxicity to microorganisms : EC50: 135 mg/l  
Exposure time: 3 h

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

**2-Pyrrolidone:**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 4,600 - 10,000 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203



## Ezetimibe Formulation

Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 500 mg/l  
Exposure time: 48 h
- Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): > 500 mg/l  
Exposure time: 72 h
- EC10 (Desmodesmus subspicatus (green algae)): 22.2 mg/l  
Exposure time: 72 h
- Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 30 min  
Method: OECD Test Guideline 209

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Ezetimibe:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 6.8 %  
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)  
Method: OECD Test Guideline 111

**Sodium n-dodecyl sulfate:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 95 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable.  
Remarks: Based on data from similar materials

**2-Pyrrolidone:**

Biodegradability : Result: Readily biodegradable.  
Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 173  
Exposure time: 97 d

# SAFETY DATA SHEET



## Ezetimibe Formulation



Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

**Sodium n-dodecyl sulfate:**

Partition coefficient: n-octanol/water : log Pow: 0.83

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**2-Pyrrolidone:**

Partition coefficient: n-octanol/water : log Pow: -0.71  
Method: OECD Test Guideline 107

**Mobility in soil**

**Components:**

**Ezetimibe:**

Distribution among environmental compartments : log Koc: 4.35  
Method: OECD Test Guideline 106

**Other adverse effects**

No data available

---

### SECTION 13. DISPOSAL CONSIDERATIONS

**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

### SECTION 14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe)  
Class : 9  
Packing group : III  
Labels : 9

**IATA-DGR**

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Ezetimibe)  
Class : 9

# SAFETY DATA SHEET



## Ezetimibe Formulation



Version 4.2      Revision Date: 16.10.2020      SDS Number: 23839-00016      Date of last issue: 23.03.2020  
Date of first issue: 21.10.2014

---

Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### NOM-002-SCT

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe)  
Class : 9  
Packing group : III  
Labels : 9

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. : Not applicable

### The ingredients of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined



# SAFETY DATA SHEET



## Ezetimibe Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.2	16.10.2020	23839-00016	Date of first issue: 21.10.2014

---

MX / Z8